PerkinElmer to Showcase Innovative Solutions to Accelerate Cancer Research at the AACR Annual Meeting 2013

  PerkinElmer to Showcase Innovative Solutions to Accelerate Cancer Research
  at the AACR Annual Meeting 2013

AACR Annual Meeting 2013

Business Wire

WALTHAM, Mass. -- April 05, 2013

At the American Association for Cancer Research 2013 Annual Meeting (Booths
1513, 1424) PerkinElmer, Inc., a global leader focused on improving the health
and safety of people and the environment, will showcase a full suite of
solutions designed to accelerate cancer research. The Company will introduce
an expanded portfolio of assays, informatics and application protocols used in
next generation sequencing (NGS) and molecular diagnostics, all designed to
advance personalized medicine-based cancer research.

“PerkinElmer is committed to advancing the improvement of human health through
better diagnosis, treatment and prevention of cancer,” said Kevin Hrusovsky,
president, Life Sciences & Technology, PerkinElmer. “At this year’s AACR, we
are excited to unveil some of our most innovative cancer research solutions
that are designed to accelerate genomic analysis, advance in-vivo tumor
visualization, and identify biomarkers that will accurately predict safety and
efficacy of biologic treatments. Advancements in next generation sequencing,
pathology and informatics are revolutionizing the way our customers create new
solutions to diagnose and treat cancer.”

At the show, PerkinElmer will launch a new genomic DNA assay for the analysis
of DNA degradation in cancer research studies. The genomic DNA assay enables
rapid automation of quality testing of DNA and RNA samples and complements a
suite of research tools for the LabChip^® GX Nucleic Acid Separation System.
Utilizing a proprietary Genomic Quality Score (GQS) algorithm that provides a
reproducible, digital quality metric, the assay is designed to ensure that
only DNA samples of the highest quality are evaluated to accelerate the NGS
workflow.

PerkinElmer will also unveil key validated protocols for NGS applications used
in cancer research using the Sciclone® NGS liquid handling workstation.
Automating the next generation sequencing process helps to avoid sample
tracking errors while reducing sample-to-sample variability and dramatically
accelerates throughput for downstream sequencing. The new Sciclone automation
protocols include:

  *KAPA ChIP Seq and KAPA HTP DNA library preparation for Illumina®
    sequencing
  *Agilent® SureSelect™ Enrichment System for Illumina® paired-ended
    sequencing library prep
  *Illumina® TruSeq™ stranded RNA protocol
  *NimbleGen® SeqCap™ EZ Library preparation/Illumina® TruSeq™ DNA sample rep

The Sciclone automated workstation also accommodates high-throughput sample
preparation for chemagen FFPE DNA extractions used in cancer research studies.

PerkinElmer will feature several poster presentations at AACR 2013:

  *Evaluating tissue expression of RANTES with subtype specific breast cancer
    biomarkers found elevated in plasma at 5PM on Sunday, April 7, 1 in Hall
    A-C, section 18, #379
  *Phenotyping TILs in situ: Automated enumeration of intra- and
    extra-follicular Foxp3+ regulatory T cells in follicular lymphoma at 5PM
    on Sunday, April 7, 1 in Hall A-C, section 21, #468
  *Generation of invasive breast cancer cell lines in vivo imaging at 5PM on
    Monday, April 8, 1—5pm Hall A-C, section 19, #3908

PerkinElmer assists researchers, clinicians and physicians to help combat
cancer in a variety of meaningful ways, including facilitating the detection
of environmental contaminants to help people avoid cancer, developing
technologies used for cancer research and providing digital flat panel
detector components for more precise imaging for diagnosing and monitoring
cancer.

Continue the conversation at AACR online by following on twitter at
@PKILifeScience with the tag #AACR.

About PerkinElmer
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.

Contact:

Edelman (on behalf of PerkinElmer)
Paul Barren, 404-460-9679
Paul.barren@edelman.com